Prothena (PRTA): Birtamimab Offers Enormous Opportunities in the Treatment of AL Amyloidosis - H.C. Wainwright Sees 207% Price Potential!
Reading Time: 3 minutes
Prothena Corporation plc (PRTA) is an Irish biopharmaceutical company. The focus of the company’s research and development is on therapeutics for the treatment of neurodegenerative diseases and rare peripheral amyloid diseases. Prothena's fully owned programs include Birtamimab for the potential treatment of AL amyloidosis, as well as a portfolio of programs for the possible treatment of Alzheimer’s disease, including PRX012, which targets Aβ (Amyloid-Beta), and PRX123, the company's dual Aβ-Tau vaccine. Prothena's collaborations include...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
